Abstract:Objectives: To evaluate the clinical implications of adjunctive molecular gene expression analysis (MMDx) of biopsy specimens in heart transplant (HT) recipients with suspected rejection. Introduction: Histopathological evaluation remains the standard method for rejection diagnosis in HT. However, the wide inter-observer variability combined with a relatively common incidence of "biopsy-negative" rejection has raised concerns about the likelihood of false-negative results. MMDx, which uses gene expression to detect early signs of rejection, is a promising test to further refine the assessment of HT rejection. Methods: Single-center prospective study of 418 consecutive for-cause endomyocardial biopsies performed between November 2022 and May 2024. Each biopsy was graded based on histology and assessed for rejection patterns using MMDx. MMDx results were deemed positive if borderline or definitive rejection was present. The impact of MMDx results on clinical management was evaluated. Primary outcomes were 1-year survival and graft dysfunction following MMDx-guided clinical management. Secondary outcomes included changes in donor-specific antibodies, MMDx gene transcripts, and donor-derived cell-free DNA (dd-cfDNA) levels. Results: We analyzed 418 molecular samples from 237 unique patients. Histology identified rejection in 32 cases (7.7%), while MMDx identified rejection in 95 cases (22.7%). Notably, in 79 of the 95 cases where MMDx identified rejection, histology results were negative, with the majority of these cases being antibody-mediated rejection (62.1%). Samples with rejection on MMDx were more likely to show a combined elevation of dd-cfDNA and peripheral blood gene expression profiling than those with borderline or negative MMDx results (36.7% vs 28.0% vs 10.3%; p<0.001). MMDx results led to the implementation of specific anti-rejection protocols or changes in immunosuppression in 20.4% of cases, and in 73.4% of cases where histology was negative and MMDx showed rejection. 1-year survival was better in the positive MMDx group where clinical management was guided by MMDx results (87.0% vs 78.6%; log rank p=0.0017). Conclusions: In our cohort, MMDx results more frequently indicated rejection than histology, often leading to the initiation of anti-rejection treatment. Intervention guided by positive MMDx results was associated with improved outcomes.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the clinical significance of molecular gene expression analysis (Molecular Microscope Diagnostic System, MMDx) in suspected rejection in heart transplant recipients. Specifically, the study aims to explore the application effect of MMDx in the auxiliary diagnosis of heart transplant rejection. In particular, when compared with traditional histopathological evaluation methods, whether MMDx can detect rejection earlier and more accurately and guide clinical treatment decisions, thereby improving the prognosis of patients. ### Research Background - **Current Standard**: Currently, the main diagnostic method for heart transplant rejection is histopathological evaluation through endomyocardial biopsy (EMB). However, this method has problems such as large inter - observer differences and relatively common "false - negative" results, which may lead to misdiagnosis or missed diagnosis. - **New Method**: MMDx is a technology based on gene expression analysis and can detect signs of early rejection. This technology is expected to improve the diagnostic accuracy of rejection and thus better guide clinical management. ### Research Objectives - **Evaluate the Clinical Value of MMDx**: By comparing the results of MMDx and traditional histopathological evaluation, evaluate the sensitivity and specificity of MMDx in diagnosing heart transplant rejection. - **Guide Clinical Management**: Explore how MMDx results affect clinical decisions, especially when the MMDx result shows rejection while the histopathological result is negative, whether the treatment plan needs to be adjusted. - **Improve Patient Prognosis**: Evaluate the impact of treatment interventions based on MMDx results on the 1 - year survival rate and graft function of patients. ### Research Methods - **Research Design**: A single - center prospective study, including 418 consecutive samples that underwent endomyocardial biopsy for suspected rejection between November 2022 and May 2024. - **Evaluation Methods**: Each biopsy sample was subjected to histopathological evaluation and MMDx analysis. A positive MMDx result was defined as the presence of marginal or definite rejection. - **Primary Outcomes**: 1 - year survival rate and the incidence of graft dysfunction. - **Secondary Outcomes**: Changes in donor - specific antibodies (DSA), MMDx gene transcripts, and donor - derived cell - free DNA (dd - cfDNA) levels. ### Main Findings - **High Sensitivity of MMDx**: MMDx identified 95 cases of rejection (22.7%) in 418 samples, while histopathology only identified 32 cases (7.7%). In particular, in 79 cases where MMDx was positive but histopathology was negative, most were antibody - mediated rejections (62.1%). - **Impact on Clinical Decisions**: MMDx results led to an adjustment of the treatment plan in 20.4% of cases, of which 73.4% of cases received anti - rejection treatment when histopathology was negative but MMDx was positive. - **Improvement in Prognosis**: The 1 - year survival rate of patients with treatment interventions based on MMDx results was 87.0%, which was significantly higher than that of patients without adjusted treatment plans (78.6%). ### Conclusions - **Advantages of MMDx**: MMDx is more sensitive than traditional histopathological evaluation in detecting heart transplant rejection, can identify rejection earlier, and thus guide clinical treatment decisions. - **Clinical Application Prospects**: Treatment interventions based on MMDx results are associated with better patient prognoses, indicating that MMDx has important clinical application value in the management of heart transplant rejection.

Clinical Utility of the Molecular Microscope Diagnostic System in a Real-World Transplant Cohort: Moving Towards a New Paradigm

Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling: the heart HistoMX system

Relationship Between Donor Derived Cell-Free DNA and Tissue-Based Rejection-Related Transcripts In Heart Transplantation

Clinical Utility of Donor‐Derived Cell‐Free DNA in Heart Transplant Recipients With Multi‐Organ Transplants

“Pre-Histologic” Antibody-Mediated Rejection Detected by Donor-Derived Cell-Free DNA and a Novel Tissue Gene Expression Assay: A Case Report

#2795 PROSPECTIVE ASSESSMENT OF THE NEED FOR AND ADDED VALUE OF MOLECULAR DIAGNOSTICS OF KIDNEY ALLOGRAFT BIOPSIES: AN EVALUATION IN CLINICAL PRACTICE

Histopathology, mRNA expression profile, and donor‐derived cell‐free DNA for assessment of rejection in pediatric heart transplantation

Antibody Mediated Rejection and T-cell Mediated Rejection Molecular Signatures Using Next-Generation Sequencing in Kidney Transplant Biopsies

Limitations of biopsy-based transcript diagnostics to detect T-cell-mediated allograft rejection

Prognostic Value of the Donor-Derived Cell-Free DNA Assay in Acute Renal Rejection Therapy: A Prospective Cohort Study.

PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation

Relationship between blood and tissue-based rejection-related transcripts in heart transplantation

Caveats in Interpretation of Molecular Diagnostics in Heart Allografts

Identification of Candidate Biomarkers in Peripheral Blood for Cardiac Allograft Rejection Based on Bioinformatics Analysis

Development of a multivariable gene-expression signature targeting T-cell-mediated rejection in peripheral blood of kidney transplant recipients validated in cross-sectional and longitudinal samples

T-cell Mediated Rejection Associated Microvascular Inflammation in the Allograft Kidney: RNAseq Analysis Using the Banff Human Organ Transplant Gene Panel

Clinical Outcomes After a Biopsy Diagnosis of Antibody-mediated Rejection in Pediatric Heart Transplant Recipients

Kidney Transplant Rejection and Tissue Injury by Gene Profiling of Biopsies and Peripheral Blood Lymphocytes

Banff Human Organ Transplant Consensus Gene Panel for the Detection of Antibody Mediated Rejection in Heart Allograft Biopsies

Molecular Signature Associated With Acute Rejection in Vascularized Composite Allotransplantation

Development and Validation of a Multiclass Model Defining Molecular Archetypes of Kidney Transplant Rejection: A Large Cohort Study of the Banff Human Organ Transplant Gene Expression Panel